Loopbaan van Thomas R. Ulich
Eerdere bekende functies van Thomas R. Ulich
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| INVIVO THERAPEUTICS HOLDINGS CORP. | Hoofd Techniek/Wetenschap/O&O | 24-02-2014 | 30-08-2017 |
ConjuChem Biotechnologies, Inc. /Old/
 ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | Hoofd Techniek/Wetenschap/O&O | 01-01-2006 | 01-01-2010 |
| ALNYLAM PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2003 | 01-01-2004 |
Amgen Canada, Inc.
 Amgen Canada, Inc. BiotechnologyHealth Technology Amgen Canada, Inc. operates as a biotechnology company. The company was founded in 1991 and is headquartered in Mississauga, Canada. | Hoofd Techniek/Wetenschap/O&O | 01-01-1993 | 01-01-2001 |
ConjuChem Biotechnologies, Inc.
 ConjuChem Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals. Its peptide products are used to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. ConjuChem Biotechnologies is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. The company was founded on August 25, 2009 and is headquartered in Montréal, Canada. | Hoofd Techniek/Wetenschap/O&O | 13-01-2010 | - |
| Wayne State University (Michigan) | Corporate Officer/Principal | - | - |
| University of California, Berkeley | Corporate Officer/Principal | - | - |
Opleiding van Thomas R. Ulich
| Dartmouth College | Undergraduate Degree |
| David Geffen School of Medicine | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 7 |
| Canada | 4 |
Operationeel
| Chief Tech/Sci/R&D Officer | 5 |
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 6 |
| Consumer Services | 5 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| INVIVO THERAPEUTICS HOLDINGS CORP. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
ConjuChem Biotechnologies, Inc. /Old/
ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | Health Technology |
Amgen Canada, Inc.
Amgen Canada, Inc. BiotechnologyHealth Technology Amgen Canada, Inc. operates as a biotechnology company. The company was founded in 1991 and is headquartered in Mississauga, Canada. | Health Technology |
ConjuChem Biotechnologies, Inc.
ConjuChem Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals. Its peptide products are used to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. ConjuChem Biotechnologies is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. The company was founded on August 25, 2009 and is headquartered in Montréal, Canada. | Health Technology |
- Beurs
- Insiders
- Thomas R. Ulich
- Ervaring
